Cat. No：GM-C09468
Product：H_TNFRSF9(4-1BB) Reporter Jurkat Cell line
Cat. No：GM-C09468
Product：H_TNFRSF9(4-1BB) Reporter Jurkat Cell line
Cell Growth Medium：RPMI 1640 +10% FBS +1% P.S +0.75 μg/mL Puromycin +3.5 μg/mL Blastincidin
Cell Freezing medium：FBS+10% DMSO
Assay Buffer：RPMI 1640 +1% FBS +1% P.S
4-1BB, also known as CD137 or TNFRSF9, is an inducible costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. It is expressed in T cells, natural killer (NK) cells, and innate immune cells. Interaction between 4-1BB and its ligand (4-1BBL) promotes cell proliferation, survival, and cytokine production. Currently, drug development targeting 4-1BB is primarily for treating inflammation, autoimmune diseases, and cancer. Agonistic antibodies targeting 4-1BB have shown promising results in treating inflammation and autoimmune diseases. Combining therapies targeting 4-1BB with immune checkpoints or costimulatory targets will enhance anti-tumor effects.
Genomeditech's H_TNFRSF9 (4-1BB) Reporter Jurkat cell line is a luciferase reporter gene cell line constructed based on 4-1BBL/4-1BB. These cells stably express the 4-1BB gene and the luciferase reporter gene, which can be used to evaluate the in vitro activation effects of therapeutic antibodies targeting 4-1BB.
The H_TNFRSF9 (4-1BB) Reporter Jurkat Cell Line can be used in combination with the H_FCGR2B CHO-K1 Cell Line (Genomeditech/GM-C16925) to assess the interaction between antibodies and the FcγRIIb receptor when crosslinked, evaluating the in vitro activation effects of antibodies.
Cat. No：GM-C09468
Product：H_TNFRSF9(4-1BB) Reporter Jurkat Cell line
Cell Growth Medium：RPMI 1640 +10% FBS +1% P.S +0.75 μg/mL Puromycin +3.5 μg/mL Blastincidin
Cell Freezing medium：FBS+10% DMSO
Assay Buffer：RPMI 1640 +1% FBS +1% P.S
4-1BB, also known as CD137 or TNFRSF9, is an inducible costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. It is expressed in T cells, natural killer (NK) cells, and innate immune cells. Interaction between 4-1BB and its ligand (4-1BBL) promotes cell proliferation, survival, and cytokine production. Currently, drug development targeting 4-1BB is primarily for treating inflammation, autoimmune diseases, and cancer. Agonistic antibodies targeting 4-1BB have shown promising results in treating inflammation and autoimmune diseases. Combining therapies targeting 4-1BB with immune checkpoints or costimulatory targets will enhance anti-tumor effects.
Genomeditech's H_TNFRSF9 (4-1BB) Reporter Jurkat cell line is a luciferase reporter gene cell line constructed based on 4-1BBL/4-1BB. These cells stably express the 4-1BB gene and the luciferase reporter gene, which can be used to evaluate the in vitro activation effects of therapeutic antibodies targeting 4-1BB.
The H_TNFRSF9 (4-1BB) Reporter Jurkat Cell Line can be used in combination with the H_FCGR2B CHO-K1 Cell Line (Genomeditech/GM-C16925) to assess the interaction between antibodies and the FcγRIIb receptor when crosslinked, evaluating the in vitro activation effects of antibodies.
